(Press-News.org) A class of drugs already on the market to lower blood pressure appears to reduce adults’ risk of developing epilepsy, Stanford Medicine researchers and their colleagues have discovered. The finding comes out of an analysis of the medical records of more than 2 million Americans taking blood pressure medications.
The study, published June 17 in JAMA Neurology, suggests that the drugs, called angiotensin receptor blockers, could prevent epilepsy in people at highest risk of the disease, including older adults who have had strokes.
“This is incredibly exciting because we don’t currently have any medicines that prevent epilepsy,” said Kimford Meador, MD, a professor of neurology and the neurosciences and the senior author of the paper. “I hope these initial findings lead to randomized clinical trials.”
Preventing seizures after stroke
While epilepsy is often diagnosed during childhood, more than 1% of people over age 65 are diagnosed with the recurring seizures that characterize the disorder. These seizures can temporarily disrupt the brain’s function and cause a range of symptoms.
In older adults, the most common risk factor for developing epilepsy is stroke; about 10% of stroke survivors experience seizures within five years. Vascular disease and chronic high blood pressure, even in the absence of stroke, also boost epilepsy risk.
“This can be a very debilitating disorder, and it’s much more common in older adults than people realize,” said Meador, a member of the Wu Tsai Neurosciences Institute.
Although anti-seizure medications can be used to control epilepsy after diagnosis, no drugs are approved to prevent epilepsy in people at high risk of developing the disorder.
During the past decade, however, studies have suggested that one type of blood pressure medication might help quell seizures because of their ability to tamp down inflammation. This aspect would be particularly apt for preventing seizures that follow stroke or traumatic brain injuries, as both cause brain inflammation that can trigger epilepsy.
In 2022, a study of more than 160,000 people in Germany found that people taking angiotensin receptor blockers — one of multiple classes of drugs prescribed to treat high blood pressure — had a diminished risk of developing epilepsy. The drugs block certain hormone receptors, leading to lower blood pressure and decreased inflammation in blood vessels and other organs — including the brain.
“Those results out of Germany echoed what had been found in animal studies and seemed very promising, but I felt that it was important to reproduce that analysis using data on people in the U.S.,” Meador said.
A bigger, broader data set
For the new study, Meador and colleagues at the University of Rhode Island turned to a national database that includes information on health care claims from more than 20 million Americans enrolled in either commercial health insurance plans or Medicare — a group more racially diverse than that in the German study. They focused their analysis on 2.2 million adults who had been diagnosed with high blood pressure, were prescribed at least one high blood pressure medication and did not already have epilepsy.
Overall, people taking angiotensin receptor blockers had a 20% to 30% lower risk of developing epilepsy between 2010 and 2017 compared with people taking other blood pressure drugs. This difference held true even when patients with strokes were removed from the analysis, suggesting that the lower rates of epilepsy were not a result solely of a decreased risk of stroke.
“What we’ve done is replicate what was found in Germany but in a larger and completely different population,” Meador said. “That really increases the strength of the signal and tells us that there’s something real going on here.”
The data also indicated that one particular angiotensin receptor blocker — losartan — had the most powerful effect on lowering epilepsy risk, but the researchers said more work is needed to confirm that.
Toward clinical trials
All blood pressure medications likely have an impact on decreasing epilepsy risk because high blood pressure is a contributing factor to epilepsy. Keeping blood pressure under control through any combination of antihypertensive drugs and lifestyle factors can therefore lower a person’s chance of developing epilepsy, Meador said.
However, the new research suggests that angiotensin receptor blockers might be more beneficial than other antihypertensives for patients to reduce the risk of epilepsy. In the new study, about 14% of people taking a blood pressure drug took angiotensin receptor blockers, while most took other classes of drugs to control their blood pressure, including beta blockers, calcium channel blockers and angiotensin-converting enzyme inhibitors.
“This could be a new chapter in the story of preventive medicine,” Meador said. “There are so many people with stroke or high blood pressure; knowing that this class of drug not only lowers blood pressure but also helps lower their epilepsy risk could change how we treat them.”
However, Meador added, randomized clinical trials are needed to prove the association between angiotensin receptor blockers and reduce epilepsy risk before treatment guidelines change.
Researchers from Brown University were also involved in the research.
The researchers have no outside funding sources or conflicts of interest to disclose.
END
Existing high blood pressure drugs may prevent epilepsy, Stanford Medicine-led study finds
Blood pressure drug may prevent epilepsy
2024-06-18
ELSE PRESS RELEASES FROM THIS DATE:
ACM recognizes innovators who solve real world problems
2024-06-18
ACM, the Association for Computing Machinery, today announced the recipients of four prestigious technical awards. These four awards in diverse categories celebrate the hard work and creativity which underpin many of today’s most important technologies.
Prateek Mittal, Princeton University, is the recipient of the 2023 ACM Grace Murray Hopper Award for foundational contributions to safeguarding Internet privacy and security using a cross-layer approach.
The unifying theme in Mittal’s ...
Wooden surfaces may have natural antiviral properties
2024-06-18
Viruses, including the coronavirus that causes COVID-19, can get passed from person to person via contaminated surfaces. But can some surfaces reduce the risk of this type of transmission without the help of household disinfectants? As reported in ACS Applied Materials & Interfaces, wood has natural antiviral properties that can reduce the time viruses persist on its surface — and some species of wood are more effective than others at reducing infectivity.
Enveloped viruses, like the coronavirus, can live up to five days on surfaces; nonenveloped viruses, including enteroviruses linked to the common cold, can live for weeks, in some cases even if the ...
For sustainable livestock farming bordering the Amazon Rainforest, look to the women
2024-06-18
When trees and livestock compete for land, the trees usually lose. It doesn’t have to be this way. But centrally designed plans to implement tree-livestock coexistence in deforested areas don’t always work on faraway farmland.
The ineffectiveness can be due to trying to accomplish too much too quickly. Transforming hundreds of thousands of hectares of treeless or degraded pastures into sustainable landscapes for livestock, nature and people should be a gradual, low-disruption process. And it should start ...
Dr. Felice J. Levine to step down as AERA Executive Director in June 2025
2024-06-18
AERA President Janelle T. Scott and Executive Director Felice J. Levine issued the following joint letter on June 18, 2024.
Dear AERA Members, Colleagues in the Field, and Leaders in Research and Education:
We are writing this joint letter to announce that Felice has decided to step down as Executive Director (ED) effective June 15, 2025. As she entered her fifth consecutive term, she signaled that she wished to move to an Emerita status next June and would not seek a further term of office. We both want to communicate this news now to provide sufficient lead time to conduct a search and ensure a smooth transition.
As ...
Treatment for autoimmune disorder acts on balance of immune cell types
2024-06-18
Autoimmune diseases cannot currently be cured, only treated, and this is also true for neuromyelitis optica spectrum disorder, which affects the central nervous system. A Kobe University study of how the treatment acts on the immune system shows that it shifts the balance of types of immune cells. This finding may represent a step toward the development of personalized medicine for autoimmune diseases.
An autoimmune disease is the body’s immune system turning against parts of the body itself. Neuromyelitis optica disorder spectrum, or NMOSD, is one of them and it causes inflammation of the central nervous system, leading to vision and sensory loss, weakness ...
Anti-inflammatory drug celecoxib could reduce risk of colon cancer recurrence for a subset of patients
2024-06-18
Boston – An analysis of data from a randomized clinical trial for patients with stage 3 colon cancer found that those with PIK3CA mutations who took celecoxib, an anti-inflammatory drug, after surgery lived significantly longer and had longer disease-free survival compared to those without the mutation. The study, highlighting a potential breakthrough in personalized cancer treatment, was led by clinical investigators at Dana-Farber Cancer Institute and Brigham and Women’s Hospital.
These findings are ...
Social inequalities widen after a breast cancer
2024-06-18
When it comes to health, inequalities can be seen at every level for women with breast cancer: prevention, screening, diagnosis, treatment, and survival. But what about their quality of life? A team from the University of Geneva (UNIGE), the University Hospitals of Geneva (HUG), Inserm, and Gustave Roussy has tracked nearly 6,000 women diagnosed with breast cancer over a 2-year period, showing that socioeconomic status has a major and lasting impact on their quality of life, despite identical medical treatment. These results from the UNICANCER-sponsored CANTO study, published in the Journal of Clinical Oncology, call ...
When does a melanoma metastasize? Implications for management
2024-06-18
“[...] immunotherapy is more likely to be effective at eliminating metastatic disease if the tumor burden is low, making it more logical to treat patients with high-risk melanomas at the earliest possible time [...]”
BUFFALO, NY- June 18, 2024 – A new research perspective was published in Oncotarget's Volume 15 on June 13, 2024, entitled, “When does a melanoma metastasize? Implications for management.”
In this new perspective, researchers John F. Thompson and Gabrielle J. Williams from The University of Sydney, Royal Prince Alfred Hospital, and the University ...
Allison Lopatkin named 2024 Pew Scholar in Biomedical Sciences
2024-06-18
Allison Lopatkin ’13, an assistant professor of chemical engineering, biomedical engineering, and microbiology and immunology at the University of Rochester, is one of 22 scientists selected to join the Pew Scholars Program in the Biomedical Sciences this year. The program provides early-career scientists four years of funding to explore some of the most pressing questions in human health and medicine.
The funding will help Lopatkin’s lab explore how changes in bacterial metabolism contribute to the development of antibiotic resistance. She says that decades of antibiotic overuse—in both clinical and agricultural ...
At least one in four US residential yards exceed new EPA lead soil level guideline
2024-06-18
American Geophysical Union
Press release 24-26
18 June 2024
For Immediate Release
This press release is available online at: https://news.agu.org/press-release/millions-households-exceed-soil-lead-epa/
At least one in four US residential yards exceed new EPA lead soil level guideline
Nearly 40% of households will exceed safety recommendations where multiple lead sources may exist. Remediation with standard techniques at this scale could cost more than $1 trillion nationally
AGU press contact:
Rebecca Dzombak, news@agu.org (UTC-4 hours)
Contact information ...
LAST 30 PRESS RELEASES:
New software sheds light on cancer’s hidden genetic networks
UT Health San Antonio awarded $3 million in CPRIT grants to bolster cancer research and prevention efforts in South Texas
Third symposium spotlights global challenge of new contaminants in China’s fight against pollution
From straw to soil harmony: International team reveals how biochar supercharges carbon-smart farming
Myeloma: How AI is redrawing the map of cancer care
Manhattan E. Charurat, Ph.D., MHS invested as the Homer and Martha Gudelsky Distinguished Professor in Medicine at the University of Maryland School of Medicine
Insilico Medicine’s Pharma.AI Q4 Winter Launch Recap: Revolutionizing drug discovery with cutting-edge AI innovations, accelerating the path to pharmaceutical superintelligence
Nanoplastics have diet-dependent impacts on digestive system health
Brain neuron death occurs throughout life and increases with age, a natural human protein drug may halt neuron death in Alzheimer’s disease
SPIE and CLP announce the recipients of the 2025 Advanced Photonics Young Innovator Award
Lessons from the Caldor Fire’s Christmas Valley ‘Miracle’
Ant societies rose by trading individual protection for collective power
Research reveals how ancient viral DNA shapes early embryonic development
A molecular gatekeeper that controls protein synthesis
New ‘cloaking device’ concept to shield sensitive tech from magnetic fields
Researchers show impact of mountain building and climate change on alpine biodiversity
Study models the transition from Neanderthals to modern humans in Europe
University of Phoenix College of Doctoral Studies releases white paper on AI-driven skilling to reduce burnout and restore worker autonomy
AIs fail at the game of visual “telephone”
The levers for a sustainable food system
Potential changes in US homelessness by ending federal support for housing first programs
Vulnerability of large language models to prompt injection when providing medical advice
Researchers develop new system for high-energy-density, long-life, multi-electron transfer bromine-based flow batteries
Ending federal support for housing first programs could increase U.S. homelessness by 5% in one year, new JAMA study finds
New research uncovers molecular ‘safety switch’ shielding cancers from immune attack
Bacteria resisting viral infection can still sink carbon to ocean floor
Younger biological age may increase depression risk in older women during COVID-19
Bharat Innovates 2026 National Basecamp Showcases India’s Most Promising Deep-Tech Ventures
Here’s what determines whether your income level rises or falls
SCIE indexation achievement: Celebrate with Space: Science & Technology
[Press-News.org] Existing high blood pressure drugs may prevent epilepsy, Stanford Medicine-led study findsBlood pressure drug may prevent epilepsy







